Union européenne - roumain - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artrita, reumatoida - imunosupresoare - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant poate fi utilizat ca monoterapie sau în asociere cu metotrexat. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Union européenne - roumain - EMA (European Medicines Agency)

eli lilly nederland b.v. - raloxifen clorhidrat - osteoporoza, postmenopauză - hormoni sexuali și modulatori ai sistemului genital, - optruma este indicat pentru tratamentul și prevenirea osteoporozei la femeile aflate în post-menopauză. sa demonstrat o reducere semnificativă a incidenței fracturilor vertebrale, dar nu și a șoldului. atunci când se determină alegerea optruma sau alte terapii, inclusiv estrogeni, pentru o femeie individuale post-menopauză, considerare ar trebui acordată simptomele menopauzei, efectele asupra uterin şi mamar tesuturi, şi riscurile cardiovasculare şi beneficii (a se vedea sectiunea 5.

Roumanie - roumain - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

eli lilly holdings limited - atomoxetinum - sol. orala - 4mg/ml - psihostimulante si nootrope simpatomimetice cu actiune centrala

Union européenne - roumain - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - sânii neoplasme - agenți antineoplazici - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Roumanie - roumain - ICBMV (Institutul pentru Controlul Produselor Biologice si Medicamentelor de Uz Veterinar)

eli lilly regional operations gmbh, austria - tilmicosin fosfat - soluţie orală - antibiotice - bovine, păsări, porcine - porcine, vitei, pui de găină (cu excepția găinilor care produc ouă pentru consum uman), pui de curcă În profilaxia (în efectivele unde diagnosticul a fost confirmat) și tratamentul unor afecțiuni determinate de microorganisme sensibile la acțiunea substanței active.

Roumanie - roumain - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

patheon france-bourgoin jalileu - franta - atomoxetinum - sol. orala - 4mg/ml - psihostimulante si nootrope simpatomimetice cu actiune centrala

Union européenne - roumain - EMA (European Medicines Agency)

eli lilly nederland b.v. - insulina lispro - diabetul zaharat - medicamente utilizate în diabet - tratamentul diabetului zaharat la adulți, adolescenți și copii cu vârsta de 1 an și peste. tratamentul diabetului zaharat la adulți.

Union européenne - roumain - EMA (European Medicines Agency)

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - agenți antineoplazici - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.

Union européenne - roumain - EMA (European Medicines Agency)

eli lilly nederland b.v. - pirtobrutinib - limfom, mantle-cell - protein kinazei - treatment of mantle cell lymphoma (mcl).

Roumanie - roumain - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lilly france s.a.s - franta - insulinum glargine - sol. inj. - 100ui/ml - insuline si alte preparate parenterale insuline si analogi cu actiune de lunga durata, injectabile